Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

Inclusion Criteria: * Healthy male or female subjects * Preferably non-smokers or smoke less than 10 cigarettes per day * Body mass index within 18 to 25 kg/m2 * Normal vital signs (after 10 minutes rest): systolic blood pressure 100 - 120 mmHg, diastolic blood pressure 60 - 80 mmHg, pulse rate 60 - 90 bpm Exclusion Criteria: * Personal / family history of allergy or hypersensitivity or contraindication to pramipexole or allied drugs * Pregnant or lactating women * Any major illness in the past 90 days or clinically significant ongoing chronic medical illness * Any clinically significant abnormal values of liver function test (ALT, alkaline phosphatase, total bilirubin \>= 1.5 upper limit normal), renal function test (serum creatinine \> 1.4 mg/dL), etc * Positive Hepatitis B surface antigen (HbsAg), anti-HCV, or anti-HIV * Clinically significant hematology abnormalities * Clinically significant ECG abnormalities * Any surgical or medical condition (present or history) which might significantly alter the pharmacokinetics of the study drug * History of anaphylaxis or angioedema * History of drug or alcohol abuse within 12 months prior to screening * Participation in any clinical trial within the past 90 days * History of any bleeding or coagulative disorders * History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm * A donation or loss of 300 mL (or more) of blood within 3 months before the study's first dosing day * Intake of any prescription, non-prescription drug, food supplement or herbal medicine within 14 days of the study's first dosing day